Novavax, CPL complete Indian vax facility

A facility for the manufacture of vaccines using Novavax's virus-like particle technology is currently undergoing validation outside Ahmadabad, India. The plant has the capacity to produce 60 million doses per year.

CPL Biologicals, a joint venture Cadila Pharmaceuticals and Novavax, announced completion of construction. The JV plans to produce seasonal and pandemic flu vaccines.

Cadila says the VLP recombinant technology will permit fast vaccine-production response for pandemics. But CPL is still lacking Indian regulatory approval to conduct clinical trials in-country for VLP-based swine flu vaccine. Meanwhile, Indian drugmakers have recently come online as producers of egg-based flu vaccines.

- here's the article

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.